Instrument Fundamentals
Date | Close | Change | Change (%) | Open | High | Low |
---|
News

AstraZeneca and Daiichi's Datroway: Groundbreaking Lung Cancer Treatment Approved in the US, ETPharma

US FDA Nod: AstraZeneca, Daiichi's Datroway Approved for Lung Cancer Treatment

AstraZeneca's Datroway Approved to Treat Non-Small Cell Lung Cancer in U.S. | Morningstar
US approves AstraZeneca, Daiichi's treatment for lung cancer

AstraZeneca To Pay $45 Mln To Daiichi Sankyo As Datroway Gets FDA Approval For Lung Cancer

The rapidly evolving paradigm of neoadjuvant immunotherapy across cancer types

BMJ investigation raises new concerns over ticagrelor approval trials

Sivik Global Healthcare LLC Acquires New Holdings in AstraZeneca PLC (NASDAQ:AZN)

First American Bank Has $1.81 Million Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Case series exploring hormonal sensitivity in prostate cancer patients harboring the germline African-ancestry HOXB13 X285K variant

Ex McDonald's Korea CEO to take leading role in Homeplus

AstraZeneca PLC (NASDAQ:AZN) Receives Average Recommendation of "Buy" from Analysts

New Swedish research initiative targets obesity and metabolic diseases

3,555 Shares in AstraZeneca PLC (NASDAQ:AZN) Bought by Wolf Group Capital Advisors

Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China | The Manila Times

Eccogene Announces First Patient Dosed in Phase 1b Trial of AZD5004/ECC5004, a Novel Oral GLP-1 Receptor Agonist, in China | Morningstar

AstraZeneca inks collaboration worth $3.6 B with CSPC Pharma focused on AI-enabled research in China

NodThera Announces Appointment of Elisabeth Björk as Board Member | The Manila Times

ADC cancer drugs: Pfizer, AstraZeneca, Merck bet on chemo replacement

NodThera Announces Appointment of Elisabeth Björk as Board Member | Morningstar

Inscription Capital LLC Makes New Investment in AstraZeneca PLC (NASDAQ:AZN)

Montecito Bank & Trust Purchases 4,328 Shares of AstraZeneca PLC (NASDAQ:AZN)

Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation
)
Sphere Bio further expands Cambridge-China's new Silk Road of trade

Second liver failure death surfaces with Sarepta's Elevidys in DMD | BioWorld

Zacks Research Forecasts Weaker Earnings for AstraZeneca

Astrazeneca makes $5.3B drug R&D pact with CSPC | BioWorld

CSPC and Astrazeneca establish strategic research collaboration | BioWorld

BRICS and the Pandemic Agreement

AstraZeneca's ENHERTU Enters Pivotal Phase 3 Trial for Endometrial Cancer

New Century Financial Group LLC Reduces Stake in AstraZeneca PLC (NASDAQ:AZN)

Elevation Point Wealth Partners LLC Boosts Holdings in AstraZeneca PLC (NASDAQ:AZN)
5 top FTSE 100 stocks offering plenty of global growth for an ISA

Shamis & Gentile, P.A. Notifies Investors It Has Filed a Complaint to Recover Losses Suffered by Purchasers of Tempus AI, Inc. and Sets a Lead Plaintiff Deadline of August 12, 2025 | Morningstar

Vietnamese PM works with top Swedish firms to foster investment ties

Stanley Laman Group Ltd. Purchases 9,614 Shares of AstraZeneca PLC (NASDAQ:AZN)

AstraZeneca signs AI research deal with China's CSPC for chronic diseases - The Economic Times

AstraZeneca Signs Nearly $5.3 Bln AI-enabled Research Deal With China's CSPC Pharma

AstraZeneca agrees to research deal worth up to $5.22 billion with CSPC

Secondary analysis of the EMPACT-MI trial reveals cardiovascular-kidney efficacy and safety of empagliflozin after acute myocardial infarction

Clonal hematopoiesis in metastatic urothelial and renal cell carcinoma

Swedish businesses asked to expand investment in Vietnam

8 Best Inexpensive Stocks to Buy Right Now

Alexion Owes Another $181M for Lack of Commercially Reasonable Efforts in Milestone Earnout Case, Chancery Rules
Cutaneous Lupus Erythematosus Market Research Report 2025-2035 - Biologic Innovations and Rising Autoimmune Incidence Fuel Growth

Assenagon Asset Management S.A. Sells 74,715 Shares of AstraZeneca PLC (NASDAQ:AZN)

RFK Jr. names new CDC vaccine advisory panel picks, STAT reports | Markets Insider
IonQ (NYSE:IONQ) Advances Quantum Computing With New Healthcare Collaboration

Merck wins approval FDA in pediatric RSV and steps into CDC uncertainty | BioWorld

Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease | Morningstar

News: AstraZeneca India appoints Praveen Rao Akkinepally new MD - People Matters

AstraZeneca Pharma slides as MD Sanjeev Panchal steps down; Praveen Rao Akkinepally to take charge | Capital Market News - Business Standard
FDA Approves Merck's RSV Antibody for Infants | Newsmax.com

US FDA approves Merck's RSV antibody for infants | U.S. & World | gazette.com

NBC Securities Inc. Purchases 3,837 Shares of AstraZeneca PLC (NASDAQ:AZN)

Merit Financial Group LLC Acquires 14,743 Shares of AstraZeneca PLC (NASDAQ:AZN)

M42, AstraZeneca & SOPHiA GENETICS launch liquid biopsy initiative in UAE
FTSE 100 shares to consider buying for a well balanced Stocks and Shares ISA

Fermata Advisors LLC Purchases New Position in AstraZeneca PLC (NASDAQ:AZN)

Adjunct-to-insulin therapy using SGLT2 inhibitors in youth with type 1 diabetes: a randomized controlled trial

Foreign firms deepen roots, strive for localization

Chesley Taft & Associates LLC Grows Position in AstraZeneca PLC (NASDAQ:AZN)

Article: Future-Ready by Design: AstraZeneca India's HR Playbook for Talent-Led Growth in GCCs - People Matters

An end-to-end attention-based approach for learning on graphs
)
AstraZeneca, BioNTech and CIC back Sortera Bio's £7.5m pre-seed round

The current and emerging immunotherapy paradigm in small-cell lung cancer

The People-First Liver Charter

AstraZeneca CEO suggests cause behind high drug prices

74,997 Shares in AstraZeneca PLC (NASDAQ:AZN) Acquired by Nixon Peabody Trust Co.

GAMMA Investing LLC Buys 573,535 Shares of AstraZeneca PLC (NASDAQ:AZN)

Trixeo Aerosphere approved in the UK as first inhaled respiratory medicine using next-generation propellant with near-zero Global Warming Potential

Win for Added Relacorilant in Platinum-Resistant Ovarian Cancer

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

Healthy Returns: AstraZeneca, Pfizer, Gilead release cancer drug data
UK Stocks That Might Be Priced Below Estimated Value

Daiichi Sankyo, AstraZeneca Announce Promising DATROWAY Combination Data in NSCLC

AstraZeneca CEO on breast cancer drug trial: This is the future of cancer treatment

AstraZeneca pill helps cut breast cancer progression risk

Experimental AstraZeneca pill helps cut risk of breast cancer progression

Stock market update: Stocks that hit 52-week highs on NSE in today's trade

52 week high stocks: Stock market update: Stocks that hit 52-week lows on NSE in today's trade - The Economic Times

AstraZeneca Reports Encouraging Data For Enhertu As 1st-line Treatment Of HER2+ Breast Cancer

Stocks to watch today, June 2: Vi, Nykaa, IndiGo, Adani Energy, AstraZeneca | Markets News - Business Standard

Stocks to Watch Today: Tata Motors, M&M, Niva Bupa, Alembic Pharma, IRCON, Godrej Properties, Titagarh, AstraZeneca, Genus Power, Nykaa in focus on 2 June

The gut microbiome as a target in cancer immunotherapy: opportunities and challenges for drug development

AstraZeneca, Daiichi announce results from three trials on DATROWAY | Markets Insider

AstraZeneca announces results from MATTERHORN Phase III trial of IMFINZI | Markets Insider

AstraZeneca announces results from SERENA-6 Phase III trial | Markets Insider

AstraZeneca breast cancer medicine slows disease by over six months

Blood test-guided treatment cuts breast cancer risk | Seymour Telegraph

Blood test-guided treatment with AstraZeneca pill cut risk of breast cancer progression, study finds
AstraZeneca News
Latest news
Show more
Morning Note: Mideast Tensions Drive Oil & Gold Volatility; Tesla Rolls Out Robotaxi

Global tensions impacted crypto market: BTC over $100K, Cardano around $0.54